208 related articles for article (PubMed ID: 34665934)
1. EGFR is a pivotal player of the E2/ERβ - mediated functional properties, aggressiveness, and stemness in triple-negative breast cancer cells.
Kyriakopoulou K; Kefali E; Piperigkou Z; Riethmüller C; Greve B; Franchi M; Götte M; Karamanos NK
FEBS J; 2022 Mar; 289(6):1552-1574. PubMed ID: 34665934
[TBL] [Abstract][Full Text] [Related]
2. ΕGFR/ERβ-Mediated Cell Morphology and Invasion Capacity Are Associated with Matrix Culture Substrates in Breast Cancer.
Kyriakopoulou K; Riti E; Piperigkou Z; Koutroumanou Sarri K; Bassiony H; Franchi M; Karamanos NK
Cells; 2020 Oct; 9(10):. PubMed ID: 33050027
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer.
Piperigkou Z; Franchi M; Götte M; Karamanos NK
Matrix Biol; 2017 Dec; 64():94-111. PubMed ID: 28797712
[TBL] [Abstract][Full Text] [Related]
4. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
Shome R; Ghosh SS
Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
[TBL] [Abstract][Full Text] [Related]
5. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
6. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor beta modulates breast cancer cells functional properties, signaling and expression of matrix molecules.
Piperigkou Z; Bouris P; Onisto M; Franchi M; Kletsas D; Theocharis AD; Karamanos NK
Matrix Biol; 2016 Dec; 56():4-23. PubMed ID: 27179695
[TBL] [Abstract][Full Text] [Related]
9. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
[TBL] [Abstract][Full Text] [Related]
10. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
12. Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.
Samanta S; Sharma VM; Khan A; Mercurio AM
Oncogene; 2012 Nov; 31(44):4689-97. PubMed ID: 22266872
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
Chen X; Yang M; Yin J; Li P; Zeng S; Zheng G; He Z; Liu H; Wang Q; Zhang F; Chen D
Cell Commun Signal; 2022 Jun; 20(1):92. PubMed ID: 35715860
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells.
Tsonis AI; Afratis N; Gialeli C; Ellina MI; Piperigkou Z; Skandalis SS; Theocharis AD; Tzanakakis GN; Karamanos NK
FEBS J; 2013 May; 280(10):2248-59. PubMed ID: 23374155
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
16. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
17. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway.
Liu T; Li K; Zhang Z; Peng J; Yang J; Law BYK; Liu X; Li W
Am J Chin Med; 2023; 51(2):425-444. PubMed ID: 36692485
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
[TBL] [Abstract][Full Text] [Related]
19. Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer.
Alexandrova E; Giurato G; Saggese P; Pecoraro G; Lamberti J; Ravo M; Rizzo F; Rocco D; Tarallo R; Nyman TA; Collina F; Cantile M; Di Bonito M; Botti G; Nassa G; Weisz A
Mol Cell Proteomics; 2020 Feb; 19(2):245-260. PubMed ID: 31792072
[TBL] [Abstract][Full Text] [Related]
20. MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells.
Pratelli G; Carlisi D; Di Liberto D; Notaro A; Giuliano M; D'Anneo A; Lauricella M; Emanuele S; Calvaruso G; De Blasio A
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
